A recent paper by Perakakis et al. [62] describes the underlying mechanistic effect of liraglutide and elafibranor, which are a GLP-1 receptor analog and a dual PPAR α/δ agonist, respectively, in regard to treatment of non-alcoholic fatty liver disease (NAFLD). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.